Geron Corporation to Present at UBS Global Specialty Pharmaceuticals Conference
Friday April 21, 7:30 am ET
MENLO PARK, Calif.--(BUSINESS WIRE)--April 21, 2006--Geron Corporation (Nasdaq:GERN - News) will be presenting an update of the company's product development programs on Monday, April 24, 2006, at the UBS Global Specialty Pharmaceuticals Conference at 9:00 a.m. Eastern Time in New York City.
ADVERTISEMENT
The update of Geron's portfolio of telomerase-based anti-cancer therapies includes GRN163L and GRNVAC1. The presentation will also include reviews of the company's human embryonic stem cell research in spinal cord injury (GRNOPC1), diabetes (GRNIPC1) and heart disease (GRNCM1). Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer, will be giving the presentation.
The audio only webcast will be available at the following website address: www.ibb.ubs.com. To access the webcast, click the Conferences icon in the center right of the page and follow the link for Webcast located next to the Global Specialty Pharmaceuticals Conference heading. The replay will be available three hours after the live presentation and will be archived for 30 days.
For further information, please contact Geron Corporation at 650-473-7765 or visit Geron's website at www.geron.com.
Geron is a biopharmaceutical company developing and commercializing three groups of products: i) therapeutic products for oncology that target telomerase; ii) pharmaceuticals that activate telomerase in tissues impacted by senescence, injury or degenerative disease; and iii) cell-based therapies derived from its human embryonic stem cell platform for applications in multiple chronic diseases. |
